Hepatitis C Virus Treatment in the 'Real-World': How Well Do 'Real' Patients Respond?

N. Deborah Friedman, Joanne H. Green, Hanna M. Weber, Shiny Stephen, Stephen E. Lane, Alvin Y. Ting, Jonathan P. Watson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Published clinical trials of the treatment of HCV are largely multicentre prospective pharmaceutical trials. Patients in clinical trials tend to have more favorable outcomes than patients in the 'real-world', due to strict patient selection and differences in treatment conditions and available resources. Objectives: To assess the outcomes of Hepatitis C infected patients treated at the Barwon Health Liver Clinic with combination Pegylated interferon (PEG-IFN) and Ribavirin (RBV) therapy and to determine factors associated with a treatment response. Methods: Retrospective review of patients who received treatment for Hepatitis C at our institution's Liver Clinic from January 2001-September 2011. Patient demographics, comorbidities, treatment-related parameters and side effects were extracted from medical records and analyzed. Results: A total of 190 patients (120 male, 70 female) with a mean age of 42.8 years (range 20-68 years) commenced treatment. The most common genotype was genotype 3 (48.9%), followed by genotype 1 (42.6%). 150 of 190 patients (78.9%) completed treatment and had end of treatment data available. 107 of 182 patients, (58.8%) for whom sustained virologic response (SVR) rate data was available achieved an SVR. Overall response rates were; 46.9%, 68.8% and 62.4% in genotypes 1, 2 and 3 respectively. The response rate was significantly lower in 29 patients with documented cirrhosis (20.7%). Age, diabetes and alcohol abuse did not predict treatment response in our cohort. Side effects reported in 81.6% of patients included general malaise, hematological disturbance and psychiatric issues, and necessitated cessation of therapy in 16 patients (8.4%) and dose reduction in 26 patients (13.7%). Conclusions: Response rates to combination PEG-IFN and RBV therapy at our institution are comparable to other 'real-world' and pharmaceutical registration trials. Side effects of combination therapy were prominent but resulted in fewer discontinuations of therapy compared to pharmaceutical trials.

Original languageEnglish
Pages (from-to)214-220
Number of pages7
JournalJournal of Clinical and Experimental Hepatology
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Hepatitis C Virus Treatment in the 'Real-World': How Well Do 'Real' Patients Respond?'. Together they form a unique fingerprint.

Cite this